Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $74M (down 86.4% year over year) with net income of −$133M.
Q1 2026 key financials · XBRL
- Revenue
- $74M
- −86.4% YoY · −72.1% QoQ
- Net income
- −$133M
- −135.8% YoY · −530.8% QoQ
- Operating margin
- -191.6%
- EPS (diluted)
- −$0.95
- −132.6% YoY · −531.8% QoQ
Source: XBRL data from the ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Q1 2026 10-Q on SEC EDGAR. USD.
ARROWHEAD PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, operating-margin, or net-income percentages disclosed
- No cash-position, operating-cash-flow, or capital-deployment figures provided
- Outlook centered on REDEMPLO sales, regulatory approval, commercial launch, clinical programs, and future cash requirements
- Headwinds include regulatory, clinical, partnership, milestone-payment, liquidity, and execution risks
Risk Factors
- No material changes to risk factors from the September 30, 2025 Form 10-K
- Carried-forward risks include biotechnology development, clinical-trial, regulatory approval, commercialization, and intellectual-property uncertainties
- New 0.00% Convertible Senior Notes due 2032 create ongoing debt-related risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARROWHEAD PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.